Breaking News

Allergan Acquires Rights to Merck’s Migraine Candidates

Two CGRP receptor antagonists in development for the treatment and prevention of migraine

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Allergan has entered an agreement to acquire the exclusive worldwide rights to Merck’s investigational small molecule oral calcitonin gene-related peptide (CGRP) receptor antagonists being developed for the treatment and prevention of migraine. Allergan will pay $250 million upfront, and Merck will be entitled to receive development and commercial milestones and royalties on sales. Allergan will be responsible for development, manufacturing and commercialization upon approval.   The two CG...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters